换一批
换一批Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study.
第一作者：
Andrew X,Zhu
第一单位：
Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA. azhu@partners.org
作者：
主题词
成年人(Adult);老年人(Aged);老年人, 80以上(Aged, 80 and over);血管生成抑制剂(Angiogenesis Inhibitors);抗体, 单克隆(Antibodies, Monoclonal);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);胆道肿瘤(Biliary Tract Neoplasms);脱氧胞苷(Deoxycytidine);无病生存(Disease-Free Survival);女(雌)性(Female);氟脱氧葡萄糖F18(Fluorodeoxyglucose F18);人类(Humans);Kaplan-Meiers评估(Kaplan-Meier Estimate);男(雄)性(Male);中年人(Middle Aged);有机铂化合物(Organoplatinum Compounds);正电子发射断层显像术(Positron-Emission Tomography);比例危险度模型(Proportional Hazards Models);放射性药物(Radiopharmaceuticals);危险性评估(Risk Assessment);时间因素(Time Factors);治疗结果(Treatment Outcome)
DOI
10.1016/S1470-2045(09)70333-X
PMID
19932054
发布时间
2020-12-12
- 浏览26
The Lancet. Oncology
48-54页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
